# Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

> **NCT00673569** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **OTHER:** immunoenzyme technique
- **OTHER:** immunologic technique
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** needle biopsy

## Key facts

- **NCT ID:** NCT00673569
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2010-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673569, "Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00673569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*